Oxaliplatin in Treating Patients With Liver Cancer

Inclusion Criteria:

* Patients must have histologically confirmed HCC which is recurrent, metastatic or unresectable
* Patients may have up to two prior chemotherapy regimes; in addition, they may have had previous radiation, chemoembolization, and/or alcohol injections
* Patients must have measurable disease, defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 20 mm with conventional techniques or as \>= 10 mm with spiral CT scan, and which has clearly progressed during the observation interval prior to participation in this study; pleural effusions and ascites will not be considered measurable, but may be present in addition to the measurable lesion(s)
* Karnofsky performance status \>= 70%; patients should have an expected survival of at least 2 months
* Leukocytes \>= 3,000/μl
* Absolute neutrophil count \>= 1,500/μl
* Platelets \>= 100,000/μl
* Total bilirubin \< 3.0 g/dl
* AST(SGOT)/ALT(SGPT) =\< 5 X institutional upper limit of normal
* Creatinine \< 2.0 OR measured creatinine clearance \>= 60 mL/min for patients with creatinine levels above institutional normal
* Brain metastasis is not an exclusion, however, patients are only eligible if they have had successful control of the brain tumor(s) by surgery or stereotactic RT
* Patients with no evidence of clinically significant neuropathy
* All prior therapy must have been completed at least 4 weeks prior to the patient's entry on this trial
* The effects of oxaliplatin on the developing human fetus at the recommended therapeutic dose are unknown; for this reason and because DNA alkylating agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
* Because the risk of toxicity in nursing infants secondary to oxaliplatin treatment of the mother is unknown but may be harmful, breastfeeding should be discontinued if the mother is treated with oxaliplatin
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* Patient has prior oxaliplatin treatment or undergoing therapy with other investigational agents
* History of allergy to platinum compounds or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy
* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, or unstable angina pectoris, or cardiac arrhythmia
* HIV-positive patients receiving anti-retroviral therapy (HAART) are excluded from the study because of possible pharmacokinetic interactions
* Patients with a diagnosis of pulmonary fibrosis or a pulmonary interstitial process